This article analyses the relevance of the published results of adjuvant chemotherapy in osteogenic osteosarcomas. It discusses the causation and prospects for treatment particularly the details of the chemotherapy, with reference to mono- or poly-chemotherapy, the influence of the dose and of the interval of administration, and also the value of pre- and post-operative chemotherapy. It is apparent that intensive pre-operative chemotherapy limited to 4 weeks is a reasonable mean of distinguishing the good responders. The problem of the choice of therapy for bad responders is also discussed.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Overexpression of miR‑424‑5p reduces cisplatin resistance by downregulating SMURF1 in gastric cancer.
Oncol Lett
March 2025
Department of General Surgery, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China.
Chemoresistance is a major obstacle in the treatment of gastric cancer (GC). Notably, aberrant expression of microRNAs (miRs) is closely related to tumor development and progression. In the present study, the role of miR-424-5p in the chemoresistance of GC was investigated.
View Article and Find Full Text PDFSingle-Session Surgical Intervention with Resection of a Primary Cranial Osteosarcoma and Cranioplasty using a 3D-Printed Craniotomy Template and Cranioplasty Molds.
J Neurol Surg Rep
January 2025
Department of Neurosurgery, Hospital of the German Armed Forces, Westerstede, Germany.
Although osteosarcomas are the most frequent primary malignant bone tumors, the primary cranial manifestation of this condition is very rare with only a limited number of cases presented in the literature. We present the case of a 20-year-old male patient who underwent single-session surgical intervention for resection of right frontal osteosarcoma with a tailor-made craniotomy and cranioplasty using virtually designed 3D-printed templates and molds. Subsequently, the patient was treated according to the EURAMOS protocol and received adjuvant systemic chemotherapy.
View Article and Find Full Text PDFUsing a machine learning algorithm and clinical data to predict the risk factors of disease recurrence after adjuvant treatment of advanced-stage oral cavity cancer.
Tzu Chi Med J
July 2024
Department of Radiation Oncology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
Objectives: Head-and-neck cancer is a major cancer in Taiwan. Most patients are in the advanced stage at initial diagnosis. In addition to primary surgery, adjuvant therapy, including chemotherapy and radiotherapy, is also necessary to treat these patients.
View Article and Find Full Text PDFThe intricate relationship between SUMOylation and gliomas: a review with a perspective on natural compounds.
Nat Prod Res
January 2025
Programa de Pós-Graduação em Biologia Celular e do Desenvolvimento, Universidade Federal de Santa Catarina, Florianópolis, Brazil.
Gliomas are tumours that affect the nervous system, with glioblastoma, also known as grade IV astrocytoma, being the most aggressive type, associated with poor prognosis. Glioblastoma is characterised by its highly invasive nature, rapid growth, and resistance to conventional chemotherapy and radiation treatments, resulting in a median survival of about 14 months. To improve patient outcomes, novel therapeutic approaches are needed.
View Article and Find Full Text PDFOutcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]).
Breast Cancer Res
January 2025
Austrian Breast & Colorectal Cancer Study Group (ABCSG), Vienna, Austria.
Background: The PALLAS trial investigated the addition of palbociclib to standard adjuvant endocrine therapy to reduce breast cancer recurrence. This pre-specified analysis was conducted to determine whether adjuvant palbociclib benefited patients diagnosed with lower risk stage IIA disease compared to those with higher stage disease.
Methods: PALLAS was an international, multicenter, randomized, open-label, phase III trial, representing a public-private partnership between Pfizer, the Austrian Breast Cancer Study Group, and the U.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!